News:

Just a reminder: if you haven't signed in for six months or more, please do so if you wish to remain active...no need to post, just sign in so we know you're still interested.

Main Menu

Truxima ( FDA Approved Biosimilar targets CD20)

Started by markt, January 27, 2019, 10:30:10 AM

Previous topic - Next topic

Sharon

"Notably, while the reference rituximab also carries indications for inflammatory diseases including rheumatoid arthritis, Celltrion sought approval only for indications in oncology."

-Does this mean it can't be prescribed for autoimmunes as well?
Sjogren's (+ RA): positive ANA, RNP, RNP-A, APCA. Severe eye dryness + inflammation, multiple sensitivities and allergic reactions, fatigue. 
ORENCIA, Restasis, Anti-inflammatory diet, Vit. D & C, Ubiquinol 100mg, Omega 3....

markt

Yes, no, maybe?

In the long run it may be a viable treatment if the biosimilar is essentially as efficous as Rituximab. 

Short term probably for NHL only.  Something I intend to ask about though.